Curcumin and its derivatives: Their application in neuropharmacology and neuroscience in the 21st century

Current Neuropharmacology

Volumn 11, Issue 4, 2013, Pages 338-378

  Lee, Wing Hin ^a   Loo, Ching Yee ^a   Bebawy, Mary ^b   Luk, Frederick ^b   Mason, Rebecca S ^a   Rohanizadeh, Ramin ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Alzheimer; Anti inflammatory; Anti oxidant; Curcumin; Glioblastoma; Parkinson; Reactive oxygen species

Indexed keywords

ALPHA SYNUCLEIN; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; PROTEASOME; UBIQUITIN;

ALZHEIMER DISEASE; ANTIMICROBIAL ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRAIN TUMOR; CELL CYCLE REGULATION; CHROMOSOME ABERRATION; COGNITION; CYTOKINE PRODUCTION; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG STABILITY; ENERGY METABOLISM; GENE MUTATION; HUMAN; LIPID PEROXIDATION; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROSCIENCE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHOTODEGRADATION; PHOTOTOXICITY; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

EID: 84899516945     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11311040002     Document Type: Article

References (434)

1. Aggarwal, B.B., Sundaram, C., Malani, N., and Ichikawa, H. Curcumin: The Indian solid gold (molecular targets and therapeutic uses of curcumin in health and disease). Adv. Exp. Med. Biol., 2007, 595, 1-75.
2. Ravindran, P.N. Turmeric-the golden spice of life in Turmeric: the genus Curcuma, Taylor and Francis Group: London, 2006, 1-14.
3. Lampe, V. Synthesis of curcumin. Ber. Dtsch. Chem. Ges., 1918, 51, 1347-1355.
4. Araujo, M.C.P., Antunes, L.M.G., and Takahashi, C.S. Protective effect of thiourea, a hydroxy/radical scavenger, on curcumininduced chromosomal aberrations in an in vitro mammalian cell system. Teratogen. Carcin. Mut., 2001, 21, 175-180.
5. Aggarwal, B.B., Takada, Y., and Oommen, O.V. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin. Investig. Drugs, 2004, 13, 1327-1338.
6. Aggarwal, B.B., Kumar, A., and Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23, 363-398.
7. Gupta, S.C., Patchva, S., Koh, W., and Aggarwal, B.B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol., 2012, 39, 283-299.
8. Pandey, A., Gupta, R.K., Bhargava, A., and Agrawal, B. Antibacterial activities of curcumin bioconjugates. Int. J. Pharmacol., 2011, 7, 874-879.
9. Kim, S.R., Park, H.J., Bae, Y.H., Ahn, S.C., Wee, H.J., Yun, I., Jang, H.O., Bae, M.K., and Bae, S.K. Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion. Endocrinology, 2012, 153, 554-563.
10. Shehzad, A., Khan, S., and Lee, Y.S. Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol., 2012, 8, 179-190.
11. Brinkevich, S.D., Ostrovskaya, N.I., Parkhach, M.E., Samovich, S.N., and Shadyro, O.I. Effects of curcumin and related compounds on processes involving alpha-hydroxyethyl radicals. Free Radical Res., 2012, 46, 295-302.
12. Moon, H.J., Ko, W.K., Han, S.W., Kim, D.S., Hwang, Y.S., Park, H.K., and Kwon, I.K. Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem. Biophys. Res. Commun., 2012, 418, 247-253.
13. Shin, S.K., Ha, T.Y., McGregor, R.A., and Choi, M.S. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol. Nutr. Food Res., 2011, 55, 1829-1840.
14. Pal, S., Choudhuri, T., Chattopadhyay, S., Bhattacharya, A., Datta, G.K., Das, T., and Sa, G. Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochem. Biophys. Res. Commun., 2001, 288, 658-665.
15. Mukundan, M.A., Chacko, M.C., Annapurna, V.V., and Krishnaswamy, K. Effect of Turmeric and Curcumin on Bp-DNA Adducts. Carcinogenesis, 1993, 14, 493-496.
16. Ray, B., Bisht, S., Maitra, A., Maitra, A., and Lahiri, D.K. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc (TM)) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J. Alzheimers Dis., 2011, 23, 61-77.
17. Mutsuga, M., Chambers, J.K., Uchida, K., Tei, M., Makibuchi, T., Mizorogi, T., Takashima, A., and Nakayama, H. Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer's brain. J. Vet. Med. Sci., 2012, 74, 51-57.
18. Mythri, R.B., Harish, G., Dubey, S.K., Misra, K., and Bharath, M.M.S. Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease. Mol. Cell. Biochem., 2011, 347, 135-143.
19. Mansouri, A., and Perry, C.A. Alteration of platelet aggregation by cigarette smoke and carbon monoxide. Thromb. Haemostasis, 1982, 48, 286-288.
20. Lim, K.J., Bisht, S., Bar, E.E., Maitra, A., and Eberhart, C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther., 2011, 11, 464-473.
21. Lee, S.J., Krauthauser, C., Maduskuie, V., Fawcett, P.T., Olson, J.M., and Rajasekaran, S.A. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer, 2011, 11, 144.
22. Purkayastha, S., Berliner, A., Fernando, S.S., Ranasinghe, B., Ray, I., Tariq, H., and Banerjee, P. Curcumin blocks brain tumor formation. Brain Res., 2009, 1266, 130-138.
23. Bangaru, M.L.Y., Woodliff, J., Raff, H., and Kansra, S. Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease. PLoS ONE, 2010, 5, e9893.
24. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem., 2006, 97, 1634-1658.
25. Waris, G., and Ahsan, H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog., 2006, 5, 14.
26. Aquilano, K., Baldelli, S., Rotilio, G., and Ciriolo, M. Role of nitric oxide synthases in Parkinson's disease: A review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem. Res., 2008, 33, 2416-2426.
27. Aggarwal, B.B., and Sung, B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci., 2009, 30, 85-94.
28. Zaidi, S.M.K.R., and Banu, N. Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. Clin. Chimica Acta, 2004, 340, 229-233.
29. Aftab, N., and Vieira, A. Antioxidant activities of curcumin and combinations of this curcuminoid with other phytochemicals. Phytother. Res., 2010, 24, 500-502.
30. Barth, S.A., Iselmann, G., Engemann, R., and Heidemann, H.T. Influences of Ginkgo biloba on cyclosporin a induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. Biochem. Pharmacol., 1991, 41, 1521-1526.
31. Procházková, D., Bouβová, I., and Wilhelmová, N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia, 2011, 82, 513-523.
32. Ali, F.E.A., Barnham, K.J., Barrow, C.J., and Separovic, F. Metalcatalyzed oxidative damage and oligomerization of the amyloidpeptide of Alzheimer's disease. Aust. J. Chem., 2004, 57, 511-518.
33. Baldeiras, I., Santana, I., Proenca, M.T., Garrucho, M.H., Pascoal, R., Rodrigues, A., Duro, D., and Oliveira, C.R. Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J. Alzheimers Dis., 2010, 21, 1165-1177.
34. Baldeiras, I., Santana, I., Proenca, M.T., Garrucho, M.H., Pascoal, R., Rodrigues, A., Duro, D., and Oliveira, C.R. Peripheral oxidative damage in Mild Cognitive Impairment and mild Alzheimer's disease. J. Alzheimers Dis., 2008, 15, 117-128.
35. Ganguli, M., Chandra, V., Kamboh, M.I., Johnston, J.M., Dodge, H.H., Thelma, B.K., Juyal, R.C., Pandav, R., Belle, S.H., and DeKosky, S.T. Apolipoprotein E polymorphism and Alzheimer disease-The Indo-US cross-national dementia study. Arch. Neurol., 2000, 57, 824-830.
36. Kim, H., Park, B.-S., Lee, K.-G., Choi, C.Y., Jang, S.S., Kim, Y.-H., and Lee, S.-E. Effects of naturally occurring compounds on fibril formation and oxidative stress of β-Amyloid. J. Agr. Food Chem., 2005, 53, 8537-8541.
37. Ryu, E.K., Choe, Y.S., Lee, K.H., Choi, Y., and Kim, B.T. Curcumin and dehydrozingerone derivatives: Synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J. Med. Chem., 2006, 49, 6111-6119.
38. Caughey, B., Raymond, L.D., Raymond, G.J., Maxson, L., Silveira, J., and Baron, G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol., 2003, 77, 5499-5502.
39. Ono, K., Hasegawa, K., Naiki, H., and Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res., 2004, 75, 742-750.
40. Garcia-Alloza, M., Borrelli, L.A., Rozkalne, A., Hyman, B.T., and Bacskai, B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem., 2007, 102, 1095-1104.
41. Lim, G.P., Chu, T., Yang, F.S., Beech, W., Frautschy, S.A., and Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21, 8370-8377.
42. Breydo, L., Wu, J.W., and Uversky, V.N. α-Synuclein misfolding and Parkinson's disease. BBA-MOL. BASIS. DIS., 2012, 1822, 261-285.
43. Beyer, K. α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol., 2006, 112, 237-251.
44. Yamakawa, K., Izumi, Y., Takeuchi, H., Yamamoto, N., Kume, T., Akaike, A., Takahashi, R., Shimohama, S., and Sawada, H. Dopamine facilitates α-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. Biochem. Biophys. Res. Commun., 2010, 391, 129-134.
45. Mythri, R.B., Jagatha, B., Pradhan, N., Andersen, J., and Bharath, M.M.S. Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria? Antioxid. Redox. Sign., 2007, 9, 399-408.
46. Jagatha, B., Mythri, R.B., Vali, S., and Bharath, M.M.S. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies. Free Radical Biol. Med., 2008, 44, 907-917.
47. Srinivas, B.M.M., Mythri, R., Jagatha, B., and Vali, S. Neuroprotective effect of curcumin against inhibition of mitochondrial complex I in vitro and in vivo: Implications for Parkinson's disease explained via in silico studies. J. Neurochem., 2008, 106, 9-28.
48. Wang, J., Du, X.X., Jiang, H., and Xie, J.X. Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappaB modulation in MES23.5 cells. Biochem. Pharmacol., 2009, 78, 178-183.
49. Chen, J., Tang, X.Q., Zhi, J.L., Cui, Y., Yu, H.M., Tang, E.H., Sun, S.N., Feng, J.Q., and Chen, P.X. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by Bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis, 2006, 11, 943-953.
50. Pandey, N., Strider, J., Nolan, W.C., Yan, S.X., and Galvin, J.E. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol., 2008, 115, 479-489.
51. Karmakar, S., Saha, A., Das, A., Banik, N.L., and Ray, S.K. Curcumin activated mutiple molecular mechanisms for apoptosis in human glioblastoma T98G cells. J. Neurochem., 2005, 94, 28-38.
52. Dhandapani, K.M., Mahesh, V.B., and Brann, D.W. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF kappa B transcription factors. J. Neurochem., 2007, 102, 522-538.
53. Dhandapani, K.M., and Brann, D.W. Cytotoxic effects of curcumin on malignant glioma cell lines. J. Neurochem., 2003, 85, 71-81.
54. Liu, E.Y., Wu, J., Cao, W.D., Zhang, J.N., Liu, W.P., Jiang, X.F., and Zhang, X.A. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J. Neuro-Oncol., 2007, 85, 263-270.
55. Aggarwal, B.B., and Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41, 40-59.
56. Cornago, P., Claramunt, R.M., Bouissane, L., Alkorta, I., and Elguero, J. A study of the tautomerism of beta-dicarbonyl compounds with special emphasis on curcuminoids. Tetrahedron, 2008, 64, 8089-8094.
57. Nie, D., Bian, Z., Yu, A., Chen, Z., Liu, Z., and Huang, C. Ground and excited state intramolecular proton transfer controlled intramolecular charge separation and recombination: A new type of charge and proton transfer reaction. Chem. Phys., 2008, 348, 181-186.
58. Bertolasi, V., Ferretti, V., Gilli, P., Yao, X., and Li, C.-J. Substituent effects on keto-enol tautomerization of [small beta]-diketones from X-ray structural data and DFT calculations. New J. Chem., 2008, 32, 694-704.
59. Jovanovic, S.V., Steenken, S., Boone, C.W., and Simic, M.G. Hatom transfer is a preferred antioxidant mechanism of curcumin. J. Am. Chem. Soc., 1999, 121, 9677-9681.
60. Wang, Y.J., Pan, M.H., Cheng, A.L., Lin, L.I., Ho, Y.S., Hsieh, C.Y., and Lin, J.K. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal., 1997, 15, 1867-1876.
61. Hatcher, H., Planalp, R., Cho, J., Tortia, F.M., and Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci., 2008, 65, 1631-1652.
62. Bernabe-Pineda, M., Ramirez-Silva, M.T., Romero-Romo, M., Gonzadlez-Vergara, E., and Rojas-Hernandez, A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim. Acta A, 2004, 60, 1091-1097.
63. Priyadarsini, K.I. Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J. Photochem. Photobiol. C, 2009, 10, 81-95.
64. Zsila, F., Bikadi, Z., and Simonyi, M. Unique, pH-dependent biphasic band shape of the visible circular dichroism of curcuminserum albumin complex. Biochem. Biophys. Res. Commun., 2003, 301, 776-782.
65. Chignell, C.F., Bilski, P., Reszka, K.J., Motten, A.G., Sik, R.H., and Dahl, T.A. Spectral and Photochemical Properties of Curcumin. Photochem. Photobiol., 1994, 59, 295-302.
66. Khopde, S.M., Priyadarsini, K., Palit, D.K., and Mukherjee, T. Effect of solvent on the excited-state photophysical properties of curcumin. Photochem. Photobiol., 2000, 72, 625-631.
67. Adhikary, R., Mukherjee, P., Kee, T.W., and Petrich, J.W. Excitedstate intramolecular hydrogen atom transfer and solvation dynamics of the medicinal pigment curcumin. J. Phys. Chem. B, 2009, 113, 5255-5261.
68. Khopde, S.M., Priyadarsini, K.I., Venkatesan, P., and Rao, M.N.A. Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophys. Chem., 1999, 80, 85-91.
69. Nardo, L., Paderno, R., Andreoni, A., Masson, M., Haukvik, T., and Tonnesen, H.H. Role of H-bond formation in the photoreactivity of curcumin. Spectrosc.-Int. J., 2008, 22, 187-198.
70. Kunnumakkara, A.B., Anand, P., and Aggarwal, B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett., 2008, 269, 199-225.
71. Tonnesen, H.H., and Karlsen, J. Studies on Curcumin and Curcuminoids .6. Kinetics of Curcumin Degradation in Aqueous-Solution. Z. Lebensm. Unters. For., 1985, 180, 402-404.
72. Price, L.C., and Buescher, R.W. Kinetics of alkaline degradation of the food pigments curcumin and curcuminoids. J. Food Sci., 1997, 62, 267-269.
73. Tonnesen, H.H., and Karlsen, J. Studies on Curcumin and Curcuminoids .5. Alkaline-Degradation of Curcumin. Z. Lebensm. Unters. For., 1985, 180, 132-134.
74. Tonnesen, H.H., Masson, M., and Loftsson, T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm., 2002, 244, 127-135.
75. Tomren, M.A., Masson, M., Loftsson, T., and Tonnesen, H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: Stability, activity and complexation with cyclodextrin. Int. J. Pharm., 2007, 338, 27-34.
76. Tonnesen, H.H., Karlsen, J., and Vanhenegouwen, G.B. Studies on Curcumin and Curcuminoids .8. Photochemical Stability of Curcumin. Z. Lebensm. Unters. For., 1986, 183, 116-122.
77. Khurana, A., and Ho, C.-T. High performance liquid chromatographic analysis of curcuminoids and their photooxidative decomposition compounds in curcuma longa L. J. Liq. Chromatogr., 1988, 11, 2295-2304.
78. Auslander, D.E., Goldberg, M., Hill, J.A., and Weiss, A.L. Naturally occuring colorants, a stability evolution. Drug Cosmet. Ind., 1977, 121, 55-57.
79. Souza, C.R.A., Osme, S.F., and Gloria, M.B.A. Stability of curcuminoid pigments in model systems. J. Food Process. Preserv., 1997, 21, 353-363.
80. Price, L.C., and Buescher, R.W. Decomposition of turmeric curcuminoids as affected by light, solvent and oxygen. J. Biol. Chem., 1996, 20, 125-133.
81. Tonnesen, H.H., and Greenhill, J.V. Studies on curcumin and curcuminoids.22. Curcumin as a reducing agent and as a radical scavenger. Int. J. Pharm., 1992, 87, 79-87.
82. Sundaryono, A., Nourmamode, A., Gardrat, C., Grelier, S., Bravic, G., Chasseau, D., and Castellan, A. Studies on the photochemistry of 1,7-diphenyl-1,6-heptadiene-3,5-dione, a non-phenolic curcuminoid model. Photochem. Photobiol. Sci., 2003, 2, 914-920.
83. Tonnesen, H.H., Devries, H., Karlsen, J., and Vanhenegouwen, G.B. Studies on curcumin and curcuminoids .9. Investigation of the photobiological activity of curcumin using bacterial indicator systems. J. Pharm. Sci., 1987, 76, 371-373.
84. Rai, D., Singh, J.K., Roy, N., and Panda, D. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. Biochem. J., 2008, 410, 147-155.
85. Jazayeri, S.D., Mustafa, S., Manap, M.Y., Ali, A.M., Ismail, A., Faujan, N.H., and Shaari, M.Y. Survival of bifidobacteria and other selected intestinal bacteria in TPY medium supplemented with curcumin as assessed in vitro. Int. J. Probiotics Prebiotics, 2009, 4, 15-22.
86. Haukvik, T., Bruzell, E., Kristensen, S., and Tonnesen, H.H. Photokilling of bacteria by curcumin in different aqueous preparations. Studies on curcumin and curcuminoids XXXVII. Pharmazie, 2009, 64, 666-673.
87. Haukvik, T., Bruzell, E., Kristensen, S., and Tonnesen, H.H. Photokilling of bacteria by curcumin in selected polyethylene glycol 400 (PEG 400) preparations. Studies on curcumin and curcuminoids, XLI. Pharmazie, 2010, 65, 600-606.
88. Haukvik, T., Bruzell, E., Kristensen, S., and Tonnesen, H.H. A screening of curcumin derivatives for antibacterial phototoxic effects. Studies on curcumin and curcuminoids. XLIII. Pharmazie, 2011, 66, 69-74.
89. Dahl, T.A., Bilski, P., Reszka, K.J., and Chignell, C.F. Photocytotoxicity of curcumin. Photochem. Photobiol., 1994, 59, 290-294.
90. Bruzell, E.M., Morisbak, E., and Tonnesen, H.H. Studies on curcumin and curcuminoids. XXIX. Photoinduced cytotoxicity of curcumin in selected aqueous preparations. Photochem. Photobiol. Sci., 2005, 4, 523-530.
91. Kundu, P., De, R., Pal, I., Mukhopadhyay, A.K., Saha, D.R., and Swarnakar, S. Curcumin alleviates matrix metalloproteinase-3 and-9 activities during eradication of Helicobacter pylori infection in cultured cells and mice. PLoS ONE, 2011, 6, e16306.
92. Foryst-Ludwig, A., Neumann, M., Schneider-Brachert, W., and Naumann, M. Curcumin blocks NF-kappa B and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem. Biophys. Res. Commun., 2004, 316, 1065-1072.
93. Wessler, S., Muenzner, P., Meyer, T.F., and Naumann, M. The anti-inflammatory compound curcumin inhibits Neisseria gonorrhoeae-induced NF-kappa B signaling, release of proinflammatory cytokines/chemokines and attenuates adhesion in late infection. Biol. Chem., 2005, 386, 481-490.
94. Marathe, S.A., Ray, S., and Chakravortty, D. Curcumin increases the pathogenicity of Salmonella enterica Serovar typhimurium in murine model. Plos. One, 2010, 5, e11511.
95. Shahverdi, A., Moghaddam, K., Yazdi, M., and Iranshahi, M. The combination effect of curcumin with different antibiotics against Staphylococcus aureus. Int. J. Green Pharm., 2009, 3, 141-143.
96. Changtam, C., Hongmanee, P., and Suksamrarn, A. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur. J. Med. Chem., 2010, 45, 4446-4457.
97. Adapala, N., and Chan, M.M. Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model. Lab. Invest., 2008, 88, 1329-1339.
98. Chan, M.M.Y., Adapala, N.S., and Fong, D. Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania. Parasitol. Res., 2005, 96, 49-56.
99. Saleheen, D., Ali, S.A., Ashfaq, K., Siddiqui, A.A., Agha, A., and Yasinzai, M.M. Latent activity of curcumin against leishmaniasis in vitro. Biol. Pharm. Bull., 2002, 25, 386-389.
100. Das, R., Roy, A., Dutta, N., and Majumder, H.K. Reactive oxygen species and imbalance of calcium homeostasis contributes to curcumin induced programmed cell death in Leishmania donovani. Apoptosis, 2008, 13, 867-882.
101. Perez-Arriaga, L., Mendoza-Magana, M.L., Cortes-Zarate, R., Corona-Rivera, A., Bobadilla-Morales, L., Troyo-Sanroman, R., and Ramirez-Herrera, M.A. Cytotoxic effect of curcumin on Giardia lamblia trophozoites. Acta Trop., 2006, 98, 152-161.
102. Cui, L., Miao, J., and Cui, L.W. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: Inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob. Agents Chemother., 2007, 51, 488-494.
103. Changtam, C., de Koning, H.P., Ibrahim, H., Sajid, M.S., Gould, M.K., and Suksamrarn, A. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur. J. Med. Chem., 2010, 45, 941-956.
104. Kim, K., Kim, K.H., Kim, H.Y., Cho, H.K., Sakamoto, N., and Cheong, J. Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway. FEBS Lett., 2010, 584, 707-712.
105. Rechtman, M.M., Bar-Yishay, I., Fishman, S., Adamovich, Y., Shaul, Y., Halpern, Z., and Shlomai, A. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1 alpha. FEBS Lett., 2010, 584, 2485-2490.
106. Tomita, M., Kawakami, H., Uchihara, J., Okudaira, T., Masuda, M., Takasu, N., Matsuda, T., Ohta, T., Tanaka, Y., and Mori, N. Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines (Retraction of vol 30, pg 313, 2006). Leukemia Res., 2011, 35, 1130-1230.
107. Prusty, B.K., and Das, B.C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer, 2005, 113, 951-960.
108. Luo, H., Zhang, J., Cheung, C., Suarez, A., McManus, B.M., and Yang, D. Proteasome inhibition reduces Coxsackievirus B3 replication in murine cardiomyocytes. Am. J. Pathol., 2003, 163, 381-385.
109. Dutta, K., Ghosh, D., and Basu, A. Curcumin Protects neuronal cells from Japanese Encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin-proteasome system. J. Neuroimmune Pharm., 2009, 4, 328-337.
110. Mazumder, A., Raghavan, K., Weinstein, J., Kohn, K.W., and Pommier, Y. Inhibition of human-immunodeficiency-virus type-1 integrase by curcumin. Biochem. Pharmacol., 1995, 49, 1165-1170.
111. Mount, C., and Downton, C. Alzheimer disease: progress or profit? Nat. Med., 2006, 12, 780-784.
112. Alonso, A.d.C., Zaidi, T., Novak, M., Grundke-Iqbal, I., and Iqbal, K. Hyperphosphorylation induces self-assembly of π into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. USA, 2001, 98, 6923-6928.
113. Ishrat, T., Hoda, M.N., Khan, M.B., Yousuf, S., Ahmad, M., Khan, M.M., Ahmad, A., and Islam, F. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur. Neuropsychopharm., 2009, 19, 636-647.
114. Medeiros, R., Baglietto-Vargas, D., and LaFerla, F.M. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci. Ther., 2011, 17, 514-524.
115. Sultana, R., Mecocci, P., Mangialasche, F., Cecchetti, R., Baglioni, M., and Butterfield, D.A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: Insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J. Alzheimers Dis., 2011, 24, 77-84.
116. Mao, P.Z., and Reddy, P.H. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics. BBA Mol. Basis Dis., 2011, 1812, 1359-1370.
117. St George-Hyslop, P.H., and Petit, A. Molecular biology and genetics of Alzheimer's disease. Comptes Rendus Biologies, 2005, 328, 119-130.
118. Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, D., Davies, P., Petersen, R.C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillebrand, M., Joosse, M., Kwon, J.M., Nowotny, P., Che, L.K., Norton, J., Morris, J.C., Reed, L.A., Trojanowski, J., Basun, H., Lannfelt, L., Neystat, M., Fahn, S., Dark, F., Tannenberg, T., Dodd, P.R., Hayward, N., Kwok, J.B.J., Schofield, P.R., Andreadis, A., Snowden, J., Craufurd, D., Neary, D., Owen, F., Oostra, B.A., Hardy, J., Goate, A., van Swieten, J., Mann, D., Lynch, T., and Heutink, P. Association of missense and 5[prime]-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393, 702-705.
119. Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J.F., Bruni, A.C., Montesi, M.P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R.J., Wasco, W., Da Silva, H.A.R., Haines, J.L., Pericak-Vance, M.A., Tanzi, R.E., Roses, A.D., Fraser, P.E., Rommens, J.M., and St. George-Hyslop, P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 1995, 375, 754-760.
120. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D., Oshima, J., Pettingell, W., Yu, C., Jondro, P., Schmidt, S., and Wang, K. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, 1995, 269, 973-977.
121. Nilsberth, C., Westlind-Danielsson, A., Eckman, C.B., Condron, M.M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D.B., Younkin, S.G., Naslund, J., and Lannfelt, L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced A[beta] protofibril formation. Nat. Neurosci., 2001, 4, 887-893.
122. Guo, Q., Fu, W., Sopher, B.L., Miller, M.W., Ware, C.B., Martin, G.M., and Mattson, M.P. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med., 1999, 5, 101-106.
123. Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N.A., Copeland, N.G., Lee, M.K., Younkin, L.H., Wagner, S.L., Younkin, S.G., and Borchelt, D.R. Mutant presenilins specifically elevate the levels of the 42 residue betaamyloid peptide in vivo: evidence for augmentation of a 42-specific beta secretase. Hum. Mol. Genet., 2004, 13, 159-170.
124. Ray, B., and Lahiri, D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol., 2009, 9, 434-444.
125. Allinson, T.M.J., Parkin, E.T., Turner, A.J., and Hooper, N.M. ADAMs family members as amyloid precursor protein β-secretases. J. Neurosci. Res., 2003, 74, 342-352.
126. Kim, S.J., Son, T.G., Park, H.R., Park, M., Kim, M.S., Kim, H.S., Chung, H.Y., Mattson, M.P., and Lee, J. Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J. Biol. Chem., 2008, 283, 14497-14505.
127. Steiner, H., and Haass, C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol, 2000, 1, 217-224.
128. Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B.L., Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B., and Selkoe, D.J. Amyloid [beta]-peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359, 322-325.
129. Refolo, L.M., Pappolla, M.A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G.S., Sambamurti, K., and Duff, K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis., 2000, 7, 321-331.
130. LaFerla, F.M., Green, K.N., and Oddo, S. Intracellular amyloid-[beta] in Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8, 499-509.
131. Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., Song, Y.-Q., Rogaeva, E., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D.-S., Holmes, E., Milman, P., Liang, Y., Zhang, D.M., Xu, D.H., Sato, C., Rogaev, E., Smith, M., Janus, C., Zhang, Y., Aebersold, R., Farrer, L., Sorbi, S., Bruni, A., Fraser, P., and St George-Hyslop, P. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and [beta]APP processing. Nature, 2000, 407, 48-54.
132. Goutte, C., Tsunozaki, M., Hale, V.A., and Priess, J.R. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 775-779.
133. Keeney, P.M., Xie, J., Capaldi, R.A., and Bennett, J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci., 2006, 26, 5256-5264.
134. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., and Wong, P.C. BACE1 is the major [beta]-secretase for generation of A[beta] peptides by neurons. Nat. Neurosci., 2001, 4, 233-234.
135. Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J.-C., Yan, Q., Richards, W.G., Citron, M., and Vassar, R. Mice deficient in BACE1, the Alzheimer's [beta]-secretase, have normal phenotype and abolished [beta]-amyloid generation. Nat. Neurosci., 2001, 4, 231-232.
136. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.-C., Collins, F., Treanor, J., Rogers, G., and Citron, M. beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286, 735-741.
137. Dayanandan, R., Van Slegtenhorst, M., Mack, T.G.A., Ko, L., Yen, S.H., Leroy, K., Brion, J.P., Anderton, B.H., Hutton, M., and Lovestone, S. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett., 1999, 446, 228-232.
138. Davignon, J., Cohn, J.S., Mabile, L., and Bernier, L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin. Chimica Acta, 1999, 286, 115-143.
139. Nickerson, D.A., Taylor, S.L., Fullerton, S.M., Weiss, K.M., Clark, A.G., Stengård, J.H., Salomaa, V., Boerwinkle, E., and Sing, C.F. Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res., 2000, 10, 1532-1545.
140. Singh, M., Arseneault, M., Sanderson, T., Murthy, V., and Ramassamy, C. Challenges for research on polyphenols from foods in Alzheimer's disease: Bioavailability, metabolism, and cellular and molecular mechanisms. J. Agr. Food Chem., 2008, 56, 4855-4873.
141. Sanan, D.A., Weisgraber, K.H., Russell, S.J., Mahley, R.W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., and Roses, A.D. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest., 1994, 94, 860-869.
142. Ophir, G., Amariglio, N., Jacob-Hirsch, J., Elkon, R., Rechavi, G., and Michaelson, D.M. Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappa B signaling cascade. Neurobiol. Dis., 2005, 20, 709-718.
143. Benzinger, T.L.S., Gregory, D.M., Burkoth, T.S., Miller-Auer, H., Lynn, D.G., Botto, R.E., and Meredith, S.C. Propagating structure of Alzheimer's β-amyloid(10-35) is parallel β-sheet with residues in exact register. Proc. Natl. Acad. Sci. USA, 1998, 95, 13407-13412.
144. Tycko, R. Insights into the Amyloid Folding Problem from Solid-State NMR. Biochemistry, 2003, 42, 3151-3159.
145. Gandy, S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J. Clin. Invest., 2005, 115, 1121-1129.
146. Harper, J.D., and Lansbury, P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407.
147. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. Isolation and quantification of soluble Alzheimer's [beta]-peptide from biological fluids. Nature, 1992, 359, 325-327.
148. Shoji, M., Golde, T., Ghiso, J., Cheung, T., Estus, S., Shaffer, L., Cai, X., McKay, D., Tintner, R., Frangione, B., and et, al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science, 1992, 258, 126-129.
149. Kuo, Y.-M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J., and Roher, A.E. Water-soluble A(N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem., 1996, 271, 4077-4081.
150. Hardy, J., and Higgins, G. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
151. Terry, R.D., Maslia, E., and Hansen, L.A. The neuropathology of Alzheimer disease and the structural basis of its cogninitve alterations. Philadelphia: Lipponcott Williams and Wilikins; 1999.
152. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., and Katzman, R. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30, 572-580.
153. Cheon, M., Chang, I., Mohanty, S., Luheshi, L.M., Dobson, C.M., Vendruscolo, M., and Favrin, G. Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput. Biol., 2007, 3, e173.
154. Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., and Ashe, K.H. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat. Neurosci., 2005, 8, 79-84.
155. Catalano, S.M., Dodson, E.C., Henze, D.A., Joyce, J.G., Krafft, G.A., and Kinney, G.G. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimers disease. Curr. Top. Med. Chem., 2006, 6, 597-608.
156. Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y.C., Kim, K.S., and Wisniewski, H.M. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 2853-2857.
157. Gyure, K.A., Durham, R., Stewart, W.F., Smialek, J.E., and Troncoso, J.C. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down Syndrome. Arch. Pathol. Lab. Med., 2001, 125, 489-492.
158. Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P., and Relkin, N.R. Intraneuronal Aβ42 Accumulation in Human Brain. Am. J. Pathol., 2000, 156, 15-20.
159. Teller, J.K., Russo, C., Debusk, L.M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D.M.A., Tabaton, M., and Gambetti, P. Presence of soluble amyloid [beta]-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med., 1996, 2, 93-95.
160. Yan, Y., and Wang, C. Aβ42 is more rigid than Aβ40 at the C terminus: Implications for Aβ aggregation and toxicity. J. Mol. Biol., 2006, 364, 853-862.
161. Butterfield, D.A., and Boyd-Kimball, D. The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity. BBA-Proteins Proteom., 2005, 1703, 149-156.
162. Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., and Selkoe, D.J. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry, 2000, 39, 10831-10839.
163. Matsuzaki, K., Noguch, T., Wakabayashi, M., Ikeda, K., Okada, T., Ohashi, Y., Hoshino, M., and Naiki, H. Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes. BBA Biomembranes, 2007, 1768, 122-130.
164. Matsuzaki, K., and Horikiri, C. Interactions of amyloid β-peptide (1β40) with ganglioside-containing membranes. Biochemistry, 1999, 38, 4137-4142.
165. Choo-Smith, L.P., Garzon-Rodriguez, W., Glabe, C.G., and Surewicz, W.K. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem., 1997, 272, 22987-90.
166. McLaurin, J., and Chakrabartty, A. Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. J. Biol. Chem., 1996, 271, 26482-26489.
167. Almeida, C.G., Takahashi, R.H., and Gouras, G.K. β-Amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci., 2006, 26, 4277-4288.
168. Gregori, L., Fuchs, C., Figueiredo-Pereira, M.E., Van Nostrand, W.E., and Goldgaber, D. Amyloid-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem., 1995, 270, 19702-19708.
169. Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., and Kirschner, M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U. S. A., 1975, 72, 1858-1862.
170. Dixit, R., Ross, J.L., Goldman, Y.E., and Holzbaur, E.L.F. Differential regulation of dynein and kinesin motor proteins by Tau. Science, 2008, 319, 1086-1089.
171. Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., and Crowther, R.A. Multiple isoforms of human microtubuleassociated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron, 1989, 3, 519-526.
172. Alonso, A.d.C., Grundke-Iqbal, I., and Iqbal, K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med., 1996, 2, 783-787.
173. Fillit, H., and Refolo, L. Tau and Alzheimer's disease. J. Mol. Neurosci., 2002, 19, 249-250.
174. Iqbal, K., Zaidi, T., Wen, G., Grundke-Iqbal, I., Merz, P., Shaikh, S., Wisniewski, H., Alafuzoff, I., and Winblad, B. Defective brain microtubule assembly in Alzheimer's disease. Lancet, 1986, 328, 421-426.
175. Köpke, E., Tung, Y.C., Shaikh, S., Alonso, A.C., Iqbal, K., and Grundke-Iqbal, I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem., 1993, 268, 24374-24384.
176. Iqbal, K., Liu, F., Gong, C.-X., Alonso, A., and Grundke-Iqbal, I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol., 2009, 118, 53-69.
177. Spillantini, M.G., Bird, T.D., and Ghetti, B. Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies. Brain Pathol., 1998, 8, 387-402.
178. Goedert, M., and Jakes, R. Mutations causing neurodegenerative tauopathies. BBA Mol. Basis Dis., 2005, 1739, 240-250.
179. von Bergen, M., Barghorn, S., Li, L., Marx, A., Biernat, J., Mandelkow, E.-M., and Mandelkow, E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local β-structure. J. Biol. Chem., 2001, 276, 48165-48174.
180. Alonso, A.d.C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol. Chem., 2004, 279, 34873-34881.
181. Nacharaju, P., Lewis, J., Easson, C., Yen, S., Hackett, J., Hutton, M., and Yen, S.-H. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett., 1999, 447, 195-199.
182. Hanger, D.P., Hughes, K., Woodgett, J.R., Brion, J.-P., and Anderton, B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett., 1992, 147, 58-62.
183. Baudier, J., and Cole, R.D. Interactions between the microtubuleassociated tau proteins and S100b regulate tau phosphorylation by the Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem., 1988, 263, 5876-5883.
184. Litersky, J.M., and Johnson, G.V. Phosphorylation by cAMPdependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem., 1992, 267, 1563-8.
185. Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., Davies, P., Burns, M., Veeranna, Nixon, R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L.-F., and Duff, K. Cdk5 Is a key factor in tau aggregation and tangle formation in vivo. Neuron, 2003, 38, 555-565.
186. Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E.-M., and Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell, 1997, 89, 297-308.
187. Tian, Q., and Wang, J. Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals, 2002, 11, 262-269.
188. Ballatore, C., Lee, V.M.Y., and Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci., 2007, 8, 663-672.
189. Mailliot, C., Trojanowski, J.Q., and Lee, V.M. Impaired tau protein function following nitration-induced oxidative stress in vitro and in vivo Neurobiol. Aging, 2002, 23 (Suppl. 1), 415.
190. Schweers, O., Mandelkow, E.M., Biernat, J., and Mandelkow, E. Oxidation of cysteine-322 in the repeat domain of microtubuleassociated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 8463-8467.
191. Halliwell, B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat. Res., 1999, 443, 37-52.
192. Halliwell, B., and Gutteridge, J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol., 1990, 186, 1-85.
193. Halliwell, B. The chemistry of free radicals. Toxicol. Ind. Health, 1993, 9, 1-21.
194. Wang, J., Xiong, S., Xie, C., Markesbery, W.R., and Lovell, M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem., 2005, 93, 953-962.
195. Shao, C., Xiong, S., Li, G.-M., Gu, L., Mao, G., Markesbery, W.R., and Lovell, M.A. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic. Biol. Med., 2008, 45, 813-819.
196. Cardoso, S.M., Proença, M.T., Santos, S., Santana, I., and Oliveira, C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging, 2004, 25, 105-110.
197. Bosetti, F., Brizzi, F., Barogi, S., Mancuso, M., Siciliano, G., Tendi, E.A., Murri, L., Rapoport, S.I., and Solaini, G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging, 2002, 23, 371-376.
198. Mutisya, E.M., Bowling, A.C., and Beal, M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem., 1994, 63, 2179-2184.
199. Chandrasekaran, K., Hatanpää, K., Brady, D.R., Stoll, J., and Rapoport, S.I. Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Brain Res., 1998, 796, 13-19.
200. Lakis, J., Glasco, S., Miller, S.W., Thal, L.J., and Davis, R.E. Production of reactive oxygen species correlates with decreased cytochrome oxidase activity in Alzheimer's disease cybrids. Soc. Neurosci., 1995, 21, 979.
201. Sheu, K.-F.R., Cooper, A.J.L., Koike, K., Koike, M., Lindsay, J.G., and Blass, J.P. Abnormality of the π-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease. Ann. Neurol., 1994, 35, 312-318.
202. Mastrogiacomo, F., Lindsay, J.G., Bettendorff, L., Rice, J., and Kish, S.J. Brain protein and π-ketoglutarate dehydrogenase complex activity in alzheimer-s disease. Ann. Neurol., 1996, 39, 592-598.
203. Behl, C., Davis, J., Cole, G.M., and Schubert, D. Vitamin E protects nerve cells from amyloid βprotein toxicity. Biochem. Biophys. Res. Commun., 1992, 186, 944-950.
204. Mark, R.J., Pang, Z., Geddes, J.W., Uchida, K., and Mattson, M.P. Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci., 1997, 17, 1046-1054.
205. Cuajungco, M.P., Goldstein, L.E., Nunomura, A., Smith, M.A., Lim, J.T., Atwood, C.S., Huang, X., Farrag, Y.W., Perry, G., and Bush, A.I. Evidence that the π-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aπ by zinc. J. Biol. Chem., 2000, 275, 19439-19442.
206. Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., and Markesbery, W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci., 1998, 158, 47-52.
207. Frederickson, C.J., Koh, J.-Y., and Bush, A.I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci., 2005, 6, 449-462.
208. Atwood, C.S., Scarpa, R.C., Huang, X., Moir, R.D., Jones, W.D., Fairlie, D.P., Tanzi, R.E., and Bush, A.I. Characterization of copper interactions with Alzheimer amyloid π peptides: Identification of an attomolar-affinity copper binding site on amyloid π1-42. J. Neurochem., 2000, 75, 1219-1233.
209. Atwood, C.S., Perry, G., Zeng, H., Kato, Y., Jones, W.D., Ling, K.Q., Huang, X., Moir, R.D., Wang, D., Sayre, L.M., Smith, M.A., Chen, S.G., and Bush, A.I. Copper mediates dityrosine crosslinking of Alzheimer's amyloid-π. Biochemistry, 2004, 43, 560-568.
210. Barnham, K.J., Haeffner, F., Ciccotosto, G.D., Curtain, C.C., Tew, D., Mavros, C., Beyreuther, K., Carrington, D., Masters, C.L., Cherny, R.A., Cappai, R., and Bush, A.I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease π-amyloid. FASEB J., 2004, 18, 1427-1429.
211. Ehmann, W.D., Markesbery, W.R., Kasarskis, E.J., Vance, D.E., Khare, S.S., Hord, J.D., and Thompson, C.M. Applications of neutron activation analysis to the study of age-related neurological diseases. Biol. Trace Elem. Res., 1987, 13, 19-33.
212. Thompson, C.B., and Jakubowski, J.A. The pathophysiology and clinical relevance of platelet heterogeneity. Blood, 1988, 72, 1-8.
213. Samudralwar, D.L., Diprete, C.C., Ni, B.F., Ehmann, W.D., and Markesbery, W.R. Elemental imbalances in the olfactory pathway in Alzheimer's disease. J. Neurol. Sci., 1995, 130, 139-145.
214. Yamamoto, A., Shin, R.-W., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., and Kitamoto, T. Iron (III) induces aggregation of hyperphosphorylated β and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem., 2002, 82, 1137-1147.
215. Emily, H., Joanna, C., Ayesha, K., Olga, K., Guy, B., and Christopher, E. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aß_(42) in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J. Alzheimer Dis., 2004, 6, 291-301.
216. Rivera-Mancía, S., Pérez-Neri, I., Ríos, C., Tristán-López, L., Rivera-Espinosa, L., and Montes, S. The transition metals copper and iron in neurodegenerative diseases. Chem. Biol. Interact., 2010, 186, 184-199.
217. Mandel, S., Amit, T., Bar-Am, O., and Youdim, M.B.H. Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol., 2007, 82, 348-360.
218. Dai, X., Sun, Y., Gao, Z., and Jiang, Z. Copper enhances amyloid-π peptide neurotoxicity and non π-aggregation: A series of experiments conducted upon copper-bound and copper-free amyloid-π peptide. J. Mol. Neurosci., 2010, 41, 66-73.
219. Hayashi, T., Shishido, N., Nakayama, K., Nunomura, A., Smith, M.A., Perry, G., and Nakamura, M. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-π peptide. Free Radic. Biol. Med., 2007, 43, 1552-1559.
220. Hung, Y.H., Bush, A.I., and Cherny, R.A. Copper in the brain and Alzheimer's disease. J. Biol. Inorg. Chem., 2010, 15, 61-76.
221. Kish, S.J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L.J., Wilson, J.M., DiStefano, L.M., and Nobrega, J.N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem., 1992, 59, 776-779.
222. Crouch, P.J., Barnham, K.J., Duce, J.A., Blake, R.E., Masters, C.L., and Trounce, I.A. Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J. Neurochem., 2006, 99, 226-236.
223. Crouch, P.J., Blake, R., Duce, J.A., Ciccotosto, G.D., Li, Q.X., Barnham, K.J., Curtain, C.C., Cherny, R.A., Cappai, R., Dyrks, T., Masters, C.L., and Trounce, I.A. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformerof amyloidbeta 1-42. J. Neurosci., 2005, 25, 672-679.
224. Strozyk, D., Launer, L.J., Adlard, P.A., Cherny, R.A., Tsatsanis, A., Volitakis, I., Blennow, K., Petrovitch, H., White, L.R., and Bush, A.I. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol. Aging, 2009, 30, 1069-1077.
225. Howell, G.A., Welch, M.G., and Frederickson, C.J. Stimulationinduced uptake and release of zinc in hippocampal slices. Nature, 1984, 308, 736-738.
226. Cardoso, S.M., Rego, A.C., Pereira, C., and Oliveira, C.R. Protective effect of zinc on amyloid-beta 25-35 and 1-40 mediated toxicity. Neurotox. Res., 2005, 7, 273-282.
227. Yoshiike, Y., Tanemura, K., Murayama, O., Akagi, T., Murayama, M., Sato, S., Sun, X., Tanaka, N., and Takashima, A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J. Biol. Chem., 2001, 276, 32293-32299.
228. Lovell, M.A., Xie, C., and Markesbery, W.R. Protection against amyloid beta peptide toxicity by zinc. Brain Res., 1999, 823, 88-95.
229. Arispe, N., Pollard, H.B., and Rojas, E. Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 1710-1715.
230. Huang, X., Atwood, C.S., Moir, R.D., Hartshorn, M.A., Vonsattel, J.P., Tanzi, R.E., and Bush, A.I. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J. Biol. Chem., 1997, 272, 26464-26470.
231. Jomova, K., Vondrakova, D., Lawson, M., and Valko, M. Metal, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem., 2010, 345, 91-104.
232. Tansey, M.G., McCoy, M.K., and Frank-Cannon, T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention Exp. Neurol., 2007, 208, 1-25.
233. Lee, Y.-J., Han, S., Nam, S.-Y., Oh, K.-W., and Hong, J. Inflammation and Alzheimer's disease. Arch. Pharmacol. Res., 2009, 33, 1539-1556.
234. Bamberger, M.E., Harris, M.E., McDonald, D.R., Husemann, J., and Landreth, G.E. A cell surface receptor complex for fibrillar amyloid mediates microglial activation. J. Neurosci., 2003, 23, 2665-2674.
235. Akiyama, H., Arai, T., Kondo, H., Tanno, E., Haga, C., and Ikeda, K. Cell mediators of inflammation in the Alzheimer disease brain Alzheimer Dis. Assoc. Disord., 2000, 14 Suppl 1, S47-S53.
236. Kitazawa, M., Yamasaki, T.R., and Laferla, F.M. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann. N. Y. Acad. Sci., 2004, 1035, 85-103.
237. Simard, A.R., Soulet, D., Gowing, G., Julien, J.P., and Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron, 2006, 49, 489-502.
238. Holmes, C., El-Okl, M., Williams, A.L., Cunningham, C., Wilcockson, D., and Perry, V.H. Systemic infection, interleukin 1, and cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2003, 74, 788-789.
239. Forlenza, O.V., Diniz, B.S., Talib, L.L., Mendonca, V.A., Ojopi, E.B., Gattaz, W.F., and Teixeira, A.L. Increased Serum IL-1beta Level in Alzheimer's Disease and Mild Cognitive Impairment. Dement. Geriatr. Cogn. Disord., 2009, 28, 507-512.
240. Wyss-Coray, T., Loike, J.D., Brionne, T.C., Lu, E., Anankov, R., Yan, F., Silverstein, S.C., and Husemann, J. Adult mouse astrocytes degrade amyloid-[beta] in vitro and in situ. Nat. Med., 2003, 9, 453-457.
241. McGeer, P.L., and McGeer, E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev., 1995, 21, 195-218.
242. McGeer, E.G., and McGeer, P.L. Inflammatory processes in Alzheimer's disease Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 741-749.
243. Mori, T., Koyama, N., Arendash, G.W., Horikoshi-Sakuraba, Y., Tan, J., and Town, T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia, 2009, 58, 300-314.
244. Simic, G., Lucassen, P.J., Krsnik, Z., Kruslin, B., Kostovic, I., Winblad, B., and Bogdanovi. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease Exp. Neurol., 2000, 165, 12-26.
245. Zhang, X., Zhang, H.M., Si, L., and Li, Y. Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer's disease. Pharmacol. Rep., 2011, 63, 1101-1108.
246. Chen, S.Y., Chen, Y., Li, Y.P., Chen, S.H., Tan, J.H., Ou, T.M., Gu, L.Q., and Huang, Z.S. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease. Bioorgan. Med. Chem., 2011, 19, 5596-5604.
247. Shytle, R.D., Bickford, P.C., Rezai-zadeh, K., Hou, L., Zeng, J., Tan, J., Sanberg, P.R., Sanberg, C.D., Roshcek, B.J., Fink, R.C., and Alberte, R.S. Optimized turmeric extracts have potent antiamyloideogenic effects. Curr. Alzheimer Res., 2009, 6, 564-571
248. Yang, F.S., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., Chen, P.P., Kayed, R., Glabe, C.G., Frautschy, S.A., and Cole, G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280, 5892-5901.
249. Khurana, S., Mediratta, P.K., Banerjee, B.D., and Sharma, K.K. Neuroprotection by curcumin and piracetam on colchicine-induced cognitive dysfunction and oxidative stress in rats. Indian J. Pharmacol., 2008, 40, 128-228.
250. Kim, D.S.H.L., Park, S.-Y., and Kim, J.-Y. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1-42) insult. Neurosci. Lett., 2001, 303, 57-61.
251. Park, S.-Y., and Kim, D.S.H.L. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult:β a drug discovery effort against Alzheimer's disease. J. Nat. Prod., 2002, 65, 1227-1231.
252. Balasubramanian, K. Molecular orbital basis for yellow curry spice curcumin's prevention of Alzheimer's disease. J. Agr. Food Chem., 2006, 54, 3512-3520.
253. Zhang, C., Browne, A., Child, D., and Tanzi, R.E. Curcumin Decreases Amyloid-beta Peptide Levels by Attenuating the Maturation of Amyloid-beta Precursor Protein. J. Biol. Chem., 2010, 285, 28472-28480.
254. Lin, R.Z., Chen, X.H., Li, W.M., Han, Y.F., Liu, P.Q., and Pi, R.B. Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: Blockage by curcumin. Neurosci. Lett., 2008, 440, 344-347.
255. Reinke, A.A., and Gestwicki, J.E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: Influence of linker length and flexibility. Chem. Biol. Drug Des., 2007, 70, 206-215.
256. Narlawar, R., Pickhardt, M., Leuchtenberger, S., Baumann, K., Krause, S., Dyrks, T., Weggen, S., Mandelkow, E., and Schmidt, B. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools' for Alzheimer's disease? Chemmedchem, 2008, 3, 165-172.
257. Orlando, R.A., Gonzales, A.M., Royer, R.E., Deck, L.M., and Vander Jagt, D.L. A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization. PLoS ONE, 2012, 7, e31869.
258. Xiao, Z.J., Lin, L.M., Liu, Z.H., Ji, F.T., Shao, W.Y., Wang, M.J., Liu, L., Li, S.L., Li, F., and Bu, X.Z. Potential therapeutic effects of curcumin: Relationship to microtubule-associated proteins 2 in A beta 1-42 insult. Brain Res., 2010, 1361, 115-123.
259. Mourtas, S., Canovi, M., Zona, C., Aurilia, D., Niarakis, A., La Ferla, B., Salmona, M., Nicotra, F., Gobbi, M., and Antimisiaris, S.G. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta 1-42 peptide. Biomaterials, 2011, 32, 1635-1645.
260. Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., and Kumar, D.S. Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease. PLoS ONE, 2012, 7, e32616.
261. Dolai, S., Shi, W., Corbo, C., Sun, C., Averick, S., Obeysekera, D., Farid, M., Alonso, A., Banerjee, P., and Raja, K. "Clicked" sugarcurcumin conjugate: modulator of amyloid-beta and tau peptide aggregation at ultralow concentrations. ACS Chem. Neurosci., 2011, 2, 694-699.
262. Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., La Ferla, B., Nicotra, F., Masserini, M., Antimisiaris, S.G., Gregori, M., and Allsop, D. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's A beta peptide. Nanomed-Nanotechnol., 2011, 7, 541-550.
263. Mathew, A., Aravind, A., Brahatheeswaran, D., Fukuda, T., Nagaoka, Y., Hasumura, T., Iwai, S., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., and Kumar, D. Amyloid-Binding Aptamer Conjugated Curcumin-PLGA Nanoparticle for Potential Use in Alzheimer's Disease. BioNanoScience, 2012, 2, 83-93.
264. Priyadarsini, K.I., Guha, S.N., and Rao, M.N.A. Physico-chemical properties and antioxidant activities of methoxy phenols. Free Rad. Biol. Med., 1998, 24, 933-941.
265. Masuda, T., Hidaka, K., Shinohara, A., Maekawa, T., Takeda, Y., and Yamaguchi, H. Chemical studies on antioxidant mechanism of curcuminoid: Analysis of radical reaction products from curcumin. J. Agr. Food Chem., 1999, 47, 71-77.
266. Cao, J., Jia, L., Zhou, H.M., Liu, Y., and Zhong, L.F. Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol. Sci., 2006, 91, 476-483.
267. Zhu, Y.G., Chen, X.C., Chen, Z.Z., Zeng, Y.Q., Shi, G.B., Su, Y.H., and Peng, X. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol. Sin., 2004, 25, 1606-1612.
268. Scapagnini, G., Colombrita, C., Amadio, M., D'Agata, V., Arcelli, E., Sapienza, M., Quattrone, A., and Calabrese, V. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid. Redox. Sign., 2006, 8, 395-403.
269. Yang, C.H., Zhang, X.J., Fan, H.G., and Liu, Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res., 2009, 1282, 133-141.
270. Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T., Giuffrida Stella, A., Schapira, T., Dinkova Kostova, A., and Rizzarelli, E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem. Res., 2008, 33, 2444-2471.
271. Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C.J., Foresti, R., Alam, J., and Motterlini, R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidantresponsive element. Biochem. J., 2003, 371, 887-895.
272. Schipper, H.M. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp. Gerontol., 2000, 35, 821-830.
273. Park, S.Y., Kim, H.S., Cho, E.K., Kwon, B.Y., Phark, S., Hwang, K.W., and Sul, D. Curcumin protected PC12 cells against betaamyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem. Toxicol., 2008, 46, 2881-2887.
274. Ghoneim, A.I., Abdel-Naim, A.B., Khalifa, A.E., and El-Denshary, E.S. Protective effects of curcumin against ischaemia/reperfusion insult in rat forebrain. Pharmacol. Res., 2002, 46, 273-279.
275. Matteucci, A., Frank, C., Domenici, M., Balduzzi, M., Paradisi, S., Carnovale-Scalzo, G., Scorcia, G., and Malchiodi-Albedi, F. Curcumin treatment protects rat retinal neurons against excitotoxicity: effect on N-methyl-D-aspartate-induced intracellular Ca2+ increase Exp. Brain Res., 2005, 167, 641-648.
276. Siddique, Y.H., Ara, G., Beg, T., Gupta, J., and Afzal, M. Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp. Toxicol. Pathol., 2010, 62, 503-508.
277. Huang, H.C., Lin, C.J., Liu, W.J., Jiang, R.R., and Jiang, Z.F. Dual effects of curcumin on neuronal oxidative stress in the presence of Cu(II). Food Chem. Toxicol., 2011, 49, 1578-1583.
278. Kakkar, V., and Kaur, I.P. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem. Toxicol., 2011, 49, 2906-2913.
279. Sethi, P., Jyoti, A., Hussain, E., and Sharma, D. Curcumin attenuates aluminium-induced functional neurotoxicity in rats. Pharmacol. Biochem. Behav., 2009, 93, 31-39.
280. Sood, P.K., and Nehru, B. Curcumin inhibits aluminium-induced mitochondrial dysfunction and apoptosis in rat brain. Free Rad. Biol. Med., 2010, 49, S157-S257.
281. Yadav, A.K., Hussain, E., and Sharma, D. Neuroprotectiveeffects of curcumin against aluminium-induced neurotoxicity in aging rats. J. Neurochem., 2010, 115, 54.
282. Baum, L., and Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis., 2004, 6, 367-377.
283. Badria, F.A., and Badria, A.F. Curcumin as anti-oxidative stress in iron toxicity. Planta Med., 2011, 77, 1384-2384.
284. Hegde, M.L., Hegde, P.M., Holthauzen, L.M., Hazra, T.K., Rao, J.K.S., and Mitra, S. Curcumin relieves copper/iron inhibition of NEIL-initiated repair of oxidized base damage in neuroblastoma cells: Therapeutic implications for neurodegenerative diseases. Movement Disord., 2011, 26, S18.
285. Zhao, X.Z., Jiang, T., Wang, L., Yang, H., Zhang, S., and Zhou, P. Interaction of curcumin with Zn(II) and Cu(II) ions based on experiment and theoretical calculation. J. Mol. Struct., 2010, 984, 316-325.
286. Jiao, Y., Wilkinson, J., Pletsch, E.C., Buss, J.L., Wang, W., Planalp, R., Torti, F.M., and Torti, S.V. Iron chelation in the biological activity of curcumin. Free Radical Biol. Med., 2006, 40, 1152-1160.
287. Garcia, C.R., Angele-Martinez, C., Wilkes, J.A., Wang, H.C., Battin, E.E., and Brumaghim, J.L. Prevention of iron-and coppermediated DNA damage by catecholamine and amino acid neurotransmitters, l-DOPA, and curcumin: metal binding as a general antioxidant mechanism. Dalton Trans., 2012, 41, 6458-6467.
288. Zhao, X.C., Zhang, L., Yu, H.X., Sun, Z., Lin, X.F., Tan, C., and Lu, R.R. Curcumin protects mouse neuroblastoma Neuro-2A cells against hydrogen-peroxide-induced oxidative stress. Food Chem., 2011, 129, 387-394.
289. Biswas, S.K., McClure, D., Jimenez, L.A., Megson, I.L., and Rahman, I. Curcumin induces glutathione biosynthesis and inhibits NF-kappa B activation and interleukin-8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity. Antioxid. Redox. Sign., 2005, 7, 32-41.
290. Huang, H.-C., Chang, P., Dai, X.-L., and Jiang, Z.-F. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem. Res., 2012, 37, 1584-1597.
291. Jung, K.K., Lee, H.S., Cho, J.Y., Shin, W.C., Rhee, M.H., Kim, T.G., Kang, J.H., Kim, S.H., Hong, S., and Kang, S.Y. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci., 2006, 79, 2022-2031.
292. Yang, S.F., Zhang, D., Yang, Z.Q., Hu, X.M., Qian, S., Liu, J., Wilson, B., Block, M., and Hong, J.S. Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem. Res., 2008, 33, 2044-2053.
293. Karlstetter, M., Lippe, E., Walczak, Y., Moehle, C., Aslanidis, A., Mirza, M., and Langmann, T. Curcumin is a potent modulator of microglial gene expression and migration. J. Neuroinflamm., 2011, 8, 125.
294. Zhang, L.J., Wu, C.F., Zhao, S.Q., Yuan, D., Lian, G.N., Wang, X.X., Wang, L.H., and Yang, J.Y. Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-kappa B signaling pathways in N9 microglia induced by lipopolysaccharide. Int. Immunopharmacol., 2010, 10, 331-338.
295. Lee, H.S., Jung, K.K., Cho, J.Y., Rhee, M.H., Hong, S., Kwon, M., Kim, S.H., and Kang, S.Y. Neuroprotective effect of curcumin is mainly mediated by blockade of microglial cell activation. Pharmazie, 2007, 62, 937-942.
296. Ringman, J.M., Frautschy, S.A., Cole, G.M., Masterman, D.L., and Cummings, J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res., 2005, 2, 131-136.
297. Frautschy, S.A., Hu, W., Kim, P., Miller, S.A., Chu, T., Harris-White, M.E., and Cole, G.M. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol. Aging, 2001, 22, 993-1005.
298. Isik, A.T., Celik, T., Ulusoy, G., Ongoru, O., Elibol, B., Doruk, H., Bozoglu, E., Kayir, H., Mas, M.R., and Akman, S. Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age, 2009, 31, 39-49.
299. Agrawal, R., Mishra, B., Tyagi, E., Nath, C., and Shukla, R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol. Res., 2010, 61, 247-252.
300. Awasthi, H., Tota, S., Hanif, K., Nath, C., and Shukla, R. Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life Sci., 2010, 86, 87-94.
301. Shen, H.-M., and Liu, Z.-G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Rad. Biol. Med., 2006, 40, 928-939.
302. Ma, Q.L., Yang, F.S., Rosario, E.R., Ubeda, O.J., Beech, W., Gant, D.J., Chen, P.P., Hudspeth, B., Chen, C.R., Zhao, Y.L., Vinters, H.V., Frautschy, S.A., and Cole, G.M. beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci., 2009, 29, 9078-9089.
303. Begum, A.N., Jones, M.R., Lim, G.P., Morihara, T., Kim, P., Heath, D.D., Rock, C.L., Pruitt, M.A., Yang, F.S., Hudspeth, B., Hu, S.X., Faull, K.F., Teter, B., Cole, G.M., and Frautschy, S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther., 2008, 326, 196-208.
304. Caesar, I., Jonson, M., Nilsson, K.P.R., Thor, S., and Hammarström, P. Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS ONE, 2012, 7, e31424.
305. Alavez, S., Vantipalli, M.C., Zucker, D.J.S., Klang, I.M., and Lithgow, G.J. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature, 2011, 472, 226-229.
306. Susan, M., and Rao, M.N.A. Induction of glutathione-s-transferase activity by curcumin in mice. Arzneimittel-Forsch., 1992, 42-2, 962-964.
307. Piper, J.T., Singhal, S.S., Salameh, M.S., Torman, R.T., Awasthi, Y.C., and Awasthi, S. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int. J. Biochem. Cell Biol., 1998, 30, 445-456.
308. Sharma, D., Sethi, P., Hussain, E., and Singh, R. Curcumin counteracts the aluminium-induced ageing-related alterations in oxidative stress, Na+, K+ ATPase and protein kinase C in adult and old rat brain regions Biogerontology, 2009, 10, 489-502.
309. Kaul, S., and Krishnakanth, T.P. Effect of retinol deficiency and curcumin or turmeric feeding on brain Na+-K+ adenosinetriphosphatase activity. Mol. Cell Biochem., 1994, 137, 101-107.
310. Bala, K., Tripathy, B.C., and Sharma, D. Neuroprotective and antiageing effects of curcumin in aged rat brain regions. Biogerontology, 2006, 7, 81-89.
311. Ataie, A., Sabetkasaei, M., Haghparast, A., Moghaddam, A.H., Ataie, R., and Moghaddam, S.N. An investigation of the neuroprotective effects of Curcumin in a model of Homocysteineinduced oxidative stress in the rat's brain. Daru-J. Pharm. Sci., 2010, 18, 128-136.
312. Sood, P.K., Nahar, U., and Nehru, B. Curcumin attenuates aluminum-induced oxidative stress and mitochondrial dysfunction in rat brain. Neurotox. Res., 2011, 20, 351-361.
313. Crambert, G., Füzesi, M., Garty, H., Karlish, S., and Geering, K. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 11476-11481.
314. Dairam, A., Fogel, R., Daya, S., and Limson, J.L. Antioxidant and iron-binding properties of curcumin, capsaicin, and S-Allylcysteine reduce oxidative stress in rat brain homogenate. J. Agr. Food Chem., 2008, 56, 3350-3356.
315. Dairam, A., Limson, J.L., Watkins, G.M., Antunes, E., and Daya, S. Curcuminoids, curcumin, and demethoxycurcumin reduce leadinduced memory deficits in male wistar rats. J. Agr. Food Chem., 2007, 55, 1039-1044.
316. Veerendra Kumar, M.H., and Gupta, Y.K. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol. Biochem. Behav., 2002, 73, 565-571.
317. Bensimon, G., and Chermat, R. Microtubule disruption and cognitive defects: Effect of colchicine on learning behavior in rats. Pharmacol. Biochem. Behav., 1991, 38, 141-145.
318. Khurana, S., Jain, S., Mediratta, P.K., Banerjee, B.D., and Sharma, K.K. Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats. Hum. Exp. Toxicol., 2012, 31, 686-697.
319. Obeso, J.A., Rodriguez-Oroz, M.C., Goetz, C.G., Marin, C., Kordower, J.H., Rodriguez, M., Hirsch, E.C., Farrer, M., Schapira, A.H., and Halliday, G. Missing pieces in the Parkinson's disease puzzle Nat. Med., 2010, 16, 653-661.
320. Shulman, J.M., De Jager, P.L., and Feany, M.B. Parkinson's disease: genetics and pathogenesis Annu. Rev. Pathol., 2011, 6, 193-222.
321. Xia, Q., Liao, L., Cheng, D., Duong, D.M., Gearing, M., Lah, J.J., Levey, A.I., and Peng, J. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci., 2008, 13, 3850-3856.
322. Anderson, J.P., Walker, D.E., Goldstein, J.M., Laat, R., Banducci, K., Caccavello, R.J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P.S., Shen, X., Chartaway, T., Schlossmacher, M.G., Seubert, P., Schenk, D., Sinha, S., Gai, W.P., and Chilcote, T.J. Phosphorylation of Ser 129 is the dominant pathological modification of synuclein in familial and sporadic Lewy body disease J. Biol. Chem., 2006, 281, 29739-29759.
323. Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropuolos, H., Trojanowski, J.Q., and Lee, V.M.Y. Oxidative damage linked to neurodegeneration by selective asynuclein nitration in synucleinopathy lesions. Science, 2000, 290, 985-989.
324. Moore, D.J., West, A.B., Dawson, V.L., and Dawson, T.M. Molecular pathophysiology of Parkinson's disease. Ann. Rev. Neurosci., 2005, 28, 57-87.
325. Dawson, T.M., and Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302, 819-822.
326. Sun, F., Kanthasamy, A., Anantharam, V., and Kanthasamy, A.G. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. Pharmacol. Ther., 2007, 114, 327-344.
327. Yavich, L., Tanila, H., Vepsalainen, S., and Jakala, P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci., 2004, 24, 11165-11170.
328. Dev, K.K., Hofele, K., Barbieri, S., Buchman, V.L., and van der Putten, H. Part II: alphasynuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 2003, 45, 14-44.
329. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., and Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-2047.
330. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D.G., and de Yebenes, J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 2004, 55, 164-173.
331. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D.S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., and Langston, J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol., 2004, 55, 174-179.
332. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., A. Takeda, Sagara, Y., Sisk, A., and Mucke, L. Dopaminergic loss and inclusion body formation in alphasynuclein mice: implications for neurodegenerative disorders. Science, 2000, 287, 1265-1269.
333. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., and Lansbury, P.T.J. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochem. J., 1996, 35, 13709-13775.
334. Perrin, R.J., Woods, W.S., Clayton, D.F., and George, J.M. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis J. Biol. Chem., 2000, 275, 34393-34398.
335. Bisaglia, M., Tessari, I., Mammi, S., and Bubacco, L. Interaction between β-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. Neuro. Mol. Med., 2009, 11, 239-251.
336. Paik, S.R., Shin, H.J., Lee, J.H., Chang, C.S., and Kim, J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J., 1999, 240, 821-828.
337. Uversky, V.N., Li, J., Bower, K., and Fink, A.L. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology, 2002, 23, 527-536.
338. Uversky, V.N., Li, J., and Fink, A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett., 2001, 500, 105-108.
339. Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T.M., and Subramaniam, V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J. Mol. Biol., 2002, 322, 383-393.
340. Smith, W.W., Margolis, R.L., Li, X., Troncoso, J.C., Lee, M.K., Dawson, V.L., Dawson, T.M., Iwatsubo, T., and Ross, C.A. β-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci., 2005, 25, 5544-5552.
341. Lee, K.-W., Chen, W., Junn, E., Im, J.-Y., Grosso, H., Sonsalla, P.K., Feng, X., Ray, N., Fernandez, J.R., Chao, Y., Masliah, E., Voronkov, M., Braithwaite, S.P., Stock, J.B., and Mouradian, M.M. Enhanced phosphatase activity attenuates β-synucleinopathy in a mouse model. J. Neurosci., 2011, 31, 6963-6971.
342. Paleologou, K.E., Oueslati, A., Shakked, G., Rospigliosi, C.C., Kim, H.-Y., Lamberto, G.R., Fernandez, C.O., Schmid, A., Chegini, F., Gai, W.P., Chiappe, D., Moniatte, M., Schneider, B.L., Aebischer, P., Eliezer, D., Zweckstetter, M., Masliah, E., and Lashuel, H.A. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits β-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci., 2010, 30, 3184-3198.
343. Navarro, A., Boveris, A., Bandez, M.J., Sanchez-Pino, M.J., Gomez, C., Muntane, G., and Ferrer, I. Human brain cortex: mitochondrial adaptive response in Parkinson's disease and in dementia with Lewy bodies. Free Rad. Biol. Med., 2009, 46, 1574-1580.
344. Berman, S.B., and Hastings, T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria. J. Neurochem., 1999, 73, 1127-1137.
345. Van Laar, V.S., Mishizen, A.J., Cascio, M., and Hastings, T.G. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis., 2009, 34, 487-500.
346. Xie, J., Marusich, M.F., Souda, P., Whitelegge, J., and Capaldi, R.A. The mitochondrial inner membrane protein Mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled-coil-helix coiledcoil-helix domain-containing protein 3 and 6 and DnaJC11. FEBS Lett., 2007, 581, 3545-3549.
347. Jin, S.M., and Youle, R.J. PINK1-and Parkin-mediated mitophagy at a glance. J. Cell Sci., 2012, 125, 795-799.
348. Gautier, C.A., Kitada, T., and Shen, J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 11364-11369.
349. Itier, J.-M., Ibanez, P., Mena, M.A., Abbas, N., Cohen-Salmon, C., Bohme, G.A., Laville, M., Pratt, J., Corti, O., Pradier, L., Ret, G., Joubert, C., Periquet, M., Araujo, F., Negroni, J., Casarejos, M.J., Canals, S., Solano, R., Serrano, A., Gallego, E., Sanchez, M., Denefle, P., Benavides, J., Tremp, G., Rooney, T.A., Brice, A., and Garcia de Yebenes, J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Gen., 2003, 12, 2277-2291.
350. Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C.J., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J.W., Vanacore, N., van Swieten, J.C., Brice, A., Meco, G., van Duijn, C.M., Oostra, B.A., and Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science, 2003, 299, 256-259.
351. Meister, A. Glutathione metabolism and its selective modification. J. Biol. Chem., 1988, 263, 17205-17208.
352. Jha, N., Jurma, O., Lalli, G., Liu, Y., Pettus, E.H., Greenamyre, J.T., Liu, R.-M., Forman, H.J., and Andersen, J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. J. Biol. Chem., 2000, 275, 26096-26101.
353. Murray, J., Taylor, S.W., Zhang, B., Ghosh, S.S., and Capaldi, R.A. Oxidative damage to mitochondrial complex I due to peroxynitrite. J. Biol. Chem., 2003, 278, 37223-37230.
354. Betarbet, R., Sherer, T.B., and Greenamyre, J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol., 2005, 191, Supplement 1, S17-S27.
355. Shashidharan, P., Good, P.F., Hsu, A., Perl, D.P., Brin, M.F., and Olanow, C.W. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res., 2000, 877, 379-381.
356. Rhodes, S.L., and Ritz, B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis., 2008, 32, 183-195.
357. Shimura, H., Hattori, N., Kubo, S.-I., Yoshikawa, M., Kitada, T., Matsumine, H., Asakawa, S., Minoshima, S., Yamamura, Y., Shimizu, N., and Mizuno, Y. Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol., 1999, 45, 668-672.
358. Rideout, H.J., Lang-Rollin, I.C.J., Savalle, M., and Stefanis, L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem., 2005, 93, 1304-1313.
359. McNaught, K.S.P., Mytilineou, C., JnoBaptiste, R., Yabut, J., Shashidharan, P., Jenner, P., and Olanow, C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem., 2002, 81, 301-306.
360. McNaught, K.S.P., Perl, D.P., Brownell, A.-L., and Olanow, C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol., 2004, 56, 149-162.
361. Tanaka, Y., Engelender, S., Igarashi, S., Rao, R.K., Wanner, T., Tanzi, R.E., Sawa, A., L. Dawson, V., Dawson, T.M., and Ross, C.A. Inducible expression of mutant β-synuclein decreases proteasome activity and increases sensitivity to mitochondriadependent apoptosis. Hum. Mol. Gen., 2001, 10, 919-926.
362. Martìn-Clemente, B., Alvarez-Castelao, B., Mayo, I., Sierra, A.B., Dìaz, V., Milán, M., Fariñas, I., Gómez-Isla, T., Ferrer, I., and Castaño, J.G. β-synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J. Biol. Chem., 2004, 279, 52984-52990.
363. Höglinger, G.U., Carrard, G., Michel, P.P., Medja, F., Lombès, A., Ruberg, M., Friguet, B., and Hirsch, E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem., 2003, 86, 1297-1307.
364. Ding, Q., Dimayuga, E., and Keller, J.N. Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid. Redox. Sign., 2006, 8, 163-172.
365. Keller, J.N., Hanni, K.B., and Markesbery, W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem., 2000, 75, 436-439.
366. Zeng, B.Y., Medhurst, A.D., Jackson, M., Rose, S., and Jenner, P. Proteasomal activity in brain differs between species and brain regions and changes with age. Mech. Ageing Dev., 2005, 126, 760-766.
367. Wang, M.S., Boddapati, S., Emadi, S., and Sierks, M.R. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci., 2010, 11, 57.
368. Liu, Z.H., Yu, Y., Li, X.P., Ross, C.A., and Smith, W.W. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol. Res., 2011, 63, 439-444.
369. Gadad, B.S., Subramanya, P.K., Pullabhatla, S., Shantharam, I.S., and Rao, K.S. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits alpha-synuclein oligomer formation: relevance to Parkinson's disease. Curr. Pharm. Design, 2012, 18, 76-84.
370. Zbarsky, V., Datla, K.P., Parkar, S., Rai, D.K., Aruoma, O.I., and Dexter, D.T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radical Res., 2005, 39, 1119-1125.
371. Jaisin, Y., Thampithak, A., Meesarapee, B., Ratanachamnong, P., Suksamrarn, A., Phivthong-ngam, L., Phumala-Morales, N., Chongthammakun, S., Govitrapong, P., and Sanvarinda, Y. Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci. Lett., 2011, 489, 192-196.
372. Rajeswari, A., and Sabesan, M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology, 2008, 16, 96-99.
373. Choi, W., Yoon, S., Oh, T.H., Eui-Ju Choi, E., O'Malley, K.L., and J., O.Y. Two distinct mechanisms are involved in 6-hydroxydopamine-and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res., 1999, 57, 86-94.
374. Saporito, M.S., Thomas, B.A., and Scott, R.W. MPTP activates cjun NH2-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem., 2000, 75, 1200-1208.
375. Yu, S., Zheng, W., Xin, N., Chi, Z.H., Wang, N.Q., Nie, Y.X., Feng, W.Y., and Wang, Z.Y. Curcumin prevents dopaminergic neuronal death through inhibition of the c-jun N-terminal kinase pathway. Rejuv. Res., 2010, 13, 55-64.
376. Liu, W.W., Fan, Z.M., Han, Y.C., Lu, S.M., Zhang, D.G., Bai, X.H., Xu, W., Li, J.F., and Wang, H.B. Curcumin attenuates peroxynitrite-induced neurotoxicity in spiral ganglion neurons. Neurotoxicology, 2011, 32, 150-157.
377. Harish, G., Venkateshappa, C., Mythri, R.B., Dubey, S.K., Mishra, K., Singh, N., Vali, S., and Bharath, M.M.S. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. Bioorgan. Med. Chem., 2010, 18, 2631-2638.
378. He, L.F., Chen, H.J., Qian, L.H., Chen, G.Y., and Buzby, J.S. Curcumin protects pre-oligodendrocytes from activated microglia in vitro and in vivo. Brain Res., 2010, 1339, 60-69.
379. Huang, W.T., Niu, K.C., Chang, C.K., Lin, M.T., and Chang, C.P. Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur. J. Pharmacol., 2008, 593, 105-111.
380. Ortiz-Ortiz, M.A., Moran, J.M., Bravosanpedro, J.M., Gonzalez-Polo, R.A., Niso-Santano, M., Anantharam, V., Kanthasamy, A.G., Soler, G., and Fuentes, J.M. Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. Neurotoxicology, 2009, 30, 1008-1018.
381. Ortiz-Ortiz, M.A., Moran, J.M., Ruiz-Mesa, L.M., Niso-Santano, M., Bravo-SanPedro, J.M., Gomez-Sanchez, R., Gonzalez-Polo, R.A., and Fuentes, J.M. Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci. Lett., 2010, 468, 120-124.
382. Polednak, A.P., and Flannery, J.T. Brain, other central-nervoussystem, and eye cancer. Cancer, 1995, 75, 330-337.
383. Hulleman, E., and Helin, K. Molecular mechanisms in gliomagenesis. In: George FVW, George K, editors. Adv. Cancer Res.: Academic Press; 2005. p. 1-27.
384. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C., and Cavenee, W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol., 2002, 61, 215-225.
385. Sonoda, Y., Ozawa, T., Aldape, K.D., Deen, D.F., Berger, M.S., and Pieper, R.O. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res., 2001, 61, 6674-6678.
386. Sherr, C.J., and Roberts, J.M. CDK inhibitors: Positive and negative regulators of G1-phase progression. Gene. Dev., 1999, 13, 1501-1512.
387. Burns, K.L., Ueki, K., Jhung, S.L., Koh, J., and Louis, D.N. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J. Neuropathol. Exp. Neurol., 1998, 57, 122-130.
388. Henson, J.W., Schnitker, B.L., Correa, K.M., Von Deimling, A., Fassbender, F., Xu, H.J., Benedict, W.F., Yandell, D.W., and Louis, D.N. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol., 1994, 36, 714-721.
389. Ichimura, K., Ohta, Y., and Tayama, N. Surgical management of the plunging ranula: a review of seven cases. J. Laryngol. Otol., 1996, 110, 554-556.
390. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman, W.H., Tom, E., Mack, D.H., and Levine, A.J. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Gene. Dev., 2000, 14, 981-993.
391. Heldin, C.H. Protein tyrosine kinase receptors. Cancer Surveys, 1996, 27, 7-24.
392. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N.P., Risau, W., and Ullrich, A. High affinity VEGF binding and development expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 1993, 72, 835-846.
393. Plate, K.H., Breier, G., Weich, H.A., and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 1992, 359, 845-847.
394. Hayashi, Y., Ueki, K., Waha, A., Wiestler, O.D., Louis, D.N., and von Deimlina, A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol., 1997, 7, 871-875.
395. Karmakar, S., Banik, N.L., and Ray, S.K. Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells. Neurochem. Res., 2007, 32, 2103-2113.
396. Karmakar, S., Banik, N.L., Patel, S.J., and Ray, S.K. Curcurnin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci. Lett., 2006, 407, 53-58.
397. Luthra, P.M., Kumar, R., and Prakash, A. Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. Biochem. Biophys. Res. Commun., 2009, 384, 420-425.
398. Huang, T.Y., Hsu, C.W., Chang, W.C., Wang, M.Y., Wu, J.F., and Hsu, Y.C. Demethoxycurcumin Retards Cell Growth and Induces Apoptosis in Human Brain Malignant Glioma GBM 8401 Cells. J. Evid. Based Complementary Altern. Med., 2012, 2012, 396573.
399. Aoki, H., Takada, Y., Kondo, S., Sawaya, R., Aggarwal, B.B., and Kondo, Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol., 2007, 72, 29-39.
400. Zhuang, W., Long, L., Zheng, B., Ji, W., Yang, N., Zhang, Q., and Liang, Z. Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Cancer Sci., 2012, 103, 684-690.
401. Woo, M.S., Jung, S.H., Kim, S.Y., Hyun, J.W., Ko, K.H., Kim, W.K., and Kim, H.S. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem. Biophys. Res. Commun., 2005, 335, 1017-1025.
402. Kim, S.Y., Jung, S.H., and Kim, H.S. Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem. Biophys. Res. Commun., 2005, 337, 510-516.
403. Perry, M.C., Demeule, M., Regina, A., Moumdjian, R., and Beliveau, R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol. Nutr. Food Res., 2010, 54, 1192-1201.
404. Zanotto-Filho, A., Braganhol, E., Edelweiss, M.I., Behr, G.A., Zanin, R., Schröder, R., Simões-Pires, A., Battastini, A.M.O., and Moreira, J.C.F. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J. Nutr. Biochem., 2012, 23, 591-601.
405. Wahlstrom, B., and Blennow, G. Study on fate of curcumin in rat. Acta Pharmacol. Tox., 1978, 43, 86-92.
406. Ravindranath, V., and Chandrasekhara, N. Absorption and Ttissue distribution of curcumin in rats. Toxicology, 1980, 16, 259-265.
407. Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Wu, M.S., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., and Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21, 2895-2900.
408. Holder, G.M., Plummer, J.L., and Ryan, A.J. Metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica, 1978, 8, 761-768.
409. Ravindranath, V., and Chandrasekhara, N. Metabolism of curcumin-studies with [H-3] curcumin. Toxicology, 1981, 22, 337-344.
410. Pan, M.H., Huang, T.M., and Lin, J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos., 1999, 27, 486-494.
411. Perkins, S., Verschoyle, R.D., Hill, K., Parveen, I., Threadgill, M.D., Sharma, R.A., Williams, M.L., Steward, W.P., and Gescher, A.J. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidem. Biomar. Prev., 2002, 11, 535-540.
412. Yang, K.-Y., Lin, L.-C., Tseng, T.-Y., Wang, S.-C., and Tsai, T.-H. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr. B, 2007, 853, 183-189.
413. Sharma, R.A., Euden, S.A., Platton, S.L., Cooke, D.N., Shafayat, A., Hewitt, H.R., Marczylo, T.H., Morgan, B., Hemingway, D., Plummer, S.M., Pirmohamed, M., Gescher, A.J., and Steward, W.P. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10, 6847-6854.
414. Garcea, G., Jones, D.J.L., Singh, R., Dennison, A.R., Farmer, P.B., Sharma, R.A., Steward, W.P., Gescher, A.J., and Berry, D.P. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer, 2004, 90, 1011-1015.
415. Garcea, G., Berry, D.P., Jones, D.J.L., Singh, R., Dennison, A.R., Farmer, P.B., Sharma, R.A., Steward, W.P., and Gescher, A.J. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 120-125.
416. Marczylo, T.H., Verschoyle, R.D., Cooke, D.N., Morazzoni, P., Steward, W.P., and Gescher, A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol., 2007, 60, 171-177.
417. Maiti, K., Mukherjee, K., Gantait, A., Saha, B.P., and Mukherjee, P.K. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm., 2007, 330, 155-163.
418. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., and Srinivas, P.S.S.R. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 1998, 64, 353-356.
419. Lao, C., Ruffin, M., Normolle, D., Heath, D., Murray, S., Bailey, J., Boggs, M., Crowell, J., Rock, C., and Brenner, D. Dose escalation of a curcuminoid formulation. BMC Complem. Altern. Med., 2006, 6, 10.
420. Goodpasture, C.E., and Arrighi, F.E. Effect of food seasoning on the cell cycle and chromosome morphology of mammalian cells in vitro with special reference to turmeric. Food Cosmet. Toxicol., 1976, 14, 9-14.
421. Sakano, K., and Kawanishi, S. Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch. Biochem. Biophys., 2002, 405, 223-230.
422. Urbina-Cano, P., Bobadilla-Morales, L., Ramirez-Herrera, M.A., Corona-Rivera, J.R., Mendoza-Magana, M.L., Troyo-Sanroman, R., and Corona-Rivera, A. DNA damage in mouse lymphocytes exposed to curcumin and copper. J. Appl. Genetics, 2006, 47, 377-382.
423. Ahsan, H., and Hadi, S.M. Strand scission in DNA induced by curcumin in the presence of Cu(II). Cancer Lett., 1998, 124, 23-30.
424. Ahsan, H., Parveen, N., Khan, N.U., and Hadi, S.M. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem-Biol. Interact., 1999, 121, 161-175.
425. Kelly, M.R., Xu, J., Alexander, K.E., and Loo, G. Disparate effects of similar phenolic phytochemicals as inhibitors of oxidative damage to cellular DNA. Mutat. Res. DNA Repair, 2001, 485, 309-318.
426. Yoshino, M., Haneda, M., Naruse, M., Htay, H.H., Tsubouchi, R., Qiao, S.L., Li, W.H., Murakami, K., and Yokochi, T. Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2-deoxyguanosine in DNA and induction of apoptotic cell death. Toxicol. In vitro, 2004, 18, 783-789.
427. Strasser, E.M., Wessner, B., Manhart, N., and Roth, E. The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. Biochem. Pharmacol., 2005, 70, 552-559.
428. Li, H., Van Berlo, D., Shi, T., Spelt, G., Knaapen, A.M., Borm, P.J.A., Albrecht, C., and Schins, R.P.F. Curcumin protects against cytotoxic and inflammatory effects of quartz particles but causes oxidative DNA damage in a rat lung epithelial cell line. Toxicol. Appl. Pharm., 2008, 227, 115-124.
429. Ireson, C., Orr, S., Jones, D.J.L., Verschoyle, R., Lim, C.K., Luo, J.L., Howells, L., Plummer, S., Jukes, R., Williams, M., Steward, W.P., and Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E-2 production. Cancer Res., 2001, 61, 1058-1064.
430. Ireson, C.R., Orr, S., Jones, D., Williams, M.L., Lim, C.K., Verschoyle, R.D., Steward, W.P., and Gescher, A.J. The metabolism of the chemopreventive agent curcumin by human gut. Br. J. Cancer, 2001, 85, 40-140.
431. Hoehle, S.I., Pfeiffer, E., Solyom, A.M., and Metzler, M. Metabolism of Curcuminoids in Tissue Slices and Subcellular Fractions from Rat Liver. J. Agr. Food Chem., 2006, 54, 756-764.
432. Anand, P., Nair, H.B., Sung, B.K., Kunnumakkara, A.B., Yadav, V.R., Tekmal, R.R., and Aggarwal, B.B. Design of curcuminloaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol., 2010, 79, 330-338.
433. Das, R.K., Kasoju, N., and Bora, U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomed. Nanotechnol. Biol. Med., 2010, 6, 153-160.
434. Mohanty, C., and Sahoo, S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials, 2010, 31, 6597-6611.